Results 11 to 20 of about 28,382 (118)

Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart

Physiological Reports, 2023
The inotropic effects of glucagon have been recognized for many years, but it has remained unclear whether glucagon signaling is beneficial to cardiac function.
Ross T. Lindsay, Philip Ambery, Lutz Jermutus, Andrew J. Murray   +3 more
doaj   +1 more source

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

PLoS ONE, 2015
AimsTo determine the effects of glucagon-like peptide-1 receptor agonists compared with placebo and other anti-diabetic agents on weight loss in overweight or obese patients with type 2 diabetes mellitus.MethodsElectronic searches were conducted for ...
Jessica E Potts, Laura J Gray, Emer M Brady, Kamlesh Khunti, Melanie J Davies, Danielle H Bodicoat   +5 more
doaj   +1 more source

Preoperative fasting for patients who take GLP-1 receptor agonists: should we Sip Til Send?

Advances in Perioperative Care
In recent years, concerns have arisen regarding the perioperative use of glucagon-like peptide-1 receptor agonist medications and a possible association with increased risk of pulmonary aspiration. The evidence in this setting remains limited.
Louisa Frances Lowes
doaj   +2 more sources

An Exceedingly Rare Case of Liraglutide-Induced Liver Injury

Case Reports in Gastrointestinal Medicine, 2021
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. We are reporting the second case of liraglutide-induced liver injury, with complete resolution of liver injury after discontinuation of ...
Swetha Parvataneni, Rajarajeshwari Ramachandran, Eric Then, Tyler Grantham, Vinaya Gaduputi   +4 more
doaj   +1 more source

A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease

Therapeutics and Clinical Risk Management, 2022
Zeyu Xie, Jinjian Li, Sensen Yang, Weishang Deng, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Li J, Yang S, Deng W, Chen J
doaj  

Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain. [PDF]

PLoS ONE, 2014
Activation of the glucagon-like peptide-1 receptor (GLP-1R) in pancreatic β-cells potentiates insulin production and is a current therapeutic target for the treatment of type 2 diabetes mellitus (T2DM).
Graham M West, Francis S Willard, Kyle W Sloop, Aaron D Showalter, Bruce D Pascal, Patrick R Griffin   +5 more
doaj   +1 more source

Effects of Treatment with Glucagon-like Peptide-1 Receptor Analogues on the Diabetic Foot

Biomedicines
Background/Objectives: Diabetic foot disease is one of the most severe and disabling complications of type 2 diabetes mellitus, resulting from the interaction between peripheral neuropathy, peripheral arterial disease, and infection.
Mercedes Ortiz Romero, David Rodríguez de Vera Gómez, Pablo Rodríguez de Vera Gómez, Luis María Gordillo Fernández   +3 more
doaj   +1 more source

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy

Journal of Cachexia, Sarcopenia and Muscle, 2019
Background Skeletal muscle atrophy is defined as a reduction of muscle mass caused by excessive protein degradation. However, the development of therapeutic interventions is still in an early stage.
Yeonhee Hong, Jong Han Lee, Kwang Won Jeong, Cheol Soo Choi, Hee‐Sook Jun   +4 more
doaj   +1 more source

Efficacy of once‐daily glucagon‐like peptide‐1 receptor agonist lixisenatide as an add‐on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐level pooled analysis of phase III studies

Journal of Diabetes Investigation, 2021
Aims/Introduction The prevalence and pathophysiological background of type 2 diabetes mellitus vary across ethnicities, and can affect treatment responses.
Fuqiang Liu, Yuan Liu, Minzhi Liu, Guangyu Wu, Minlu Zhang, Xia Zhang, Nan Cui, Huiqiu Yin, Li Chen   +8 more
doaj   +1 more source

Cardioprotective Actions of a Glucagon‐like Peptide‐1 Receptor Agonist on Hearts Donated After Circulatory Death

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Heart transplantation with a donation after circulatory death (DCD) heart is complicated by substantial organ ischemia and ischemia–reperfusion injury. Exenatide, a glucagon‐like peptide−1 receptor agonist, manifests protection against cardiac
Sachiko Kadowaki, M. Ahsan Siraj, Weiden Chen, Jian Wang, Marlee Parker, Anita Nagy, Chun‐Po Steve Fan, Kyle Runeckles, Jing Li, Junko Kobayashi, Christoph Haller, Mansoor Husain, Osami Honjo   +12 more
doaj   +1 more source